Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Next Previous
Trial Profile

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms PIONEER 6; PIONEER6
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 26 Jun 2023 Results using individual-level participant data from LEADER , SUSTAIN 6 and PIONEER 6 , comparing cardiovascular (CV) protective effect of liraglutide vs semaglutide in subjects with type 2 diabetes, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
    • 01 Apr 2023 Results of pooled post hoc analysis (n=6480 from two studies SUSTAIN 6/PIONEER 6) assessing the effects of semaglutide versus placebo on eGFR decline published in the Kidney International
    • 23 Sep 2022 Results of pooled post-hoc analysis from two clinical studies: SUSTAIN 6 and PIONEER 6 assessing association between baseline kidney function and risk of MACE and effect of semaglutide on risk of MACE by baseline kidney function presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top